Analysts have been eager to weigh in on the Healthcare sector with new ratings on Knight Therapeutics (KHTRF – Research Report), Tarsus Pharmaceuticals (TARS – Research Report) and Illumina (ILMN – Research Report).
Knight Therapeutics (KHTRF)
In a report released today, Justin Keywood from Stifel Nicolaus maintained a Hold rating on Knight Therapeutics, with a price target of C$5.25. The company’s shares closed last Thursday at $3.56.
According to TipRanks.com, Keywood is ranked #6489 out of 8643 analysts.
Knight Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $4.29.
See today’s best-performing stocks on TipRanks >>
Tarsus Pharmaceuticals (TARS)
In a report released today, Francois Brisebois from Oppenheimer assigned a Buy rating to Tarsus Pharmaceuticals, with a price target of $55.00. The company’s shares closed last Friday at $17.15.
According to TipRanks.com, Brisebois is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Tarsus Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $50.00, which is a 192.9% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $50.00 price target.
Illumina (ILMN)
In a report released today, David Westenberg from Piper Sandler maintained a Buy rating on Illumina, with a price target of $200.00. The company’s shares closed last Friday at $92.20.
According to TipRanks.com, Westenberg is a 1-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Illumina with a $155.71 average price target, which is a 65.6% upside from current levels. In a report released today, TD Cowen also maintained a Buy rating on the stock with a $144.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on KHTRF:
